新股消息 泽璟制药(688266.SH)递表港交所

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor, indicating its intent to expand its capital base for further development in the biopharmaceutical sector [1] Group 1: Company Overview - Zelgen Biopharmaceutical is a comprehensive biopharmaceutical company focused on the discovery, research and development, and commercialization of innovative small molecules and biological agents [1] - The company strategically focuses on three therapeutic areas: oncology, autoimmune diseases, and hemostasis/blood disorders [1] Group 2: Product Portfolio - Zelgen Biopharmaceutical has a product portfolio that includes marketed drugs, late-stage clinical candidates, and early-stage innovative discovery projects [1] - The company currently has three marketed drugs: - Zepu Sheng, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China - Zepu Ping, the first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis - Zepu Ning, the only recombinant human thrombin developed and successfully commercialized using recombinant DNA technology in China [1]